Joel Lewis - 16 Jan 2026 Form 4/A - Amendment Insider Report for GALECTIN THERAPEUTICS INC (GALT)

Reporting relationship: President and CEO, Director
Issuer ticker: GALT
Reported as of: 16 Jan 2026
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 22 Jan 2026, 14:11:05 UTC
Original report date: 21 Jan 2026
Prior SEC filing: 13 Jan 2026
Source filing: View source filing
Reporting owner signature: Jack W. Callicutt

Key filing fact

Joel Lewis filed Form 4/A - Amendment for GALECTIN THERAPEUTICS INC (GALT) on 22 Jan 2026.

Key facts

This page summarizes Joel Lewis's Form 4/A - Amendment filing for GALECTIN THERAPEUTICS INC (GALT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 22 Jan 2026, 14:11.

Change

Previous filing in this sequence was filed on 13 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001725595 Primary reporting owner

LEWIS JOEL

Relationship: President and CEO, Director
Address: C/O GALECTIN THERAPEUTICS INC., 4960 PEACHTREE INDUSTRIAL BLVD., STE 240, NORCROSS
Signature: Jack W. Callicutt
Signature date: 22 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GALT transaction Derivative

Stock option (right to buy)

Award

Transaction value: $0
Shares: +91,000
Change %
Price: $0.000000
Shares after: 91,000
Date: 16 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 91,000
Exercise price: $3.04
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

Footnote F2

The options vest as follows: 25% on each of June 30, 2026? December 31, 2026? June 30, 2027? and December 31, 2027.

Footnote F3

The original Form 4 filed had an incorrect number of common stock options. This amendment presents the correct number of common stock options granted.